New hope for Hard-to-Treat colorectal cancer: experimental drug combo enters human trials
NCT ID NCT06936527
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests a new oral drug called XS-03 combined with standard chemotherapy and a targeted antibody (bevacizumab) in 102 people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if the combination is safe and shrinks tumors better than current treatments. It is an early-phase trial, so the main focus is on safety and finding the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XS-03 (oral drug) combined with chemotherapy (FOLFOX or FOLFIRI) and bevacizumab (injected antibody)
What this could lead to
If successful, this could offer a new treatment option for people with a hard-to-treat form of colorectal cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is an early-phase trial (1b/2) with only 102 participants, so results may not apply broadly. The combination may cause significant side effects, and the added benefit of XS-03 is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China